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Cachexia is a syndrome associated with cancer, characterized by body weight loss, muscle and adipose tissue wasting, and
inflammation, being often associated with anorexia. In spite of the fact that muscle tissue represents more than 40% of body
weight and seems to be the main tissue involved in the wasting that occurs during cachexia, recent developments suggest that
tissues/organs such as adipose (both brown and white), brain, liver, gut, and heart are directly involved in the cachectic process and
may be responsible for muscle wasting. This suggests that cachexia is indeed a multiorgan syndrome. Bearing all this in mind, the
aim of the present review is to examine the impact of nonmuscle tissues in cancer cachexia.
1. Cachexia as an Energy-Wasting Syndrome
Cachexia, from the Greek: “kakos” and “hexis,” meaning “bad
condition,” is a multiorgan syndrome associated with cancer
and other systemic diseases such as sepsis and renal failure
and characterized by at least 5% body weight loss due to
muscle and adipose tissue wasting and inflammation [1].
Abnormalities associated with cachexia include alterations
in carbohydrate, lipid, and protein metabolism [2]. Cancer
cachexia has been characterized as a syndrome associated
with loss of muscle with or without loss of fat mass. Other
disorders associated with cachexia are anorexia, inflamma-
tion, insulin resistance, and increased muscle protein [2].
Another defining characteristic is that cachexia cannot be
fully reversed by conventional nutritional support and leads
to progressive functional impairment [3]. Thus, it can be
concluded that cachexia is caused by an energy imbalance
which is the result of both decreased food intake, due to
marked anorexia, and increased energy expenditure caused
by a highly hypermetabolic state. Blum et al. [4] in a
recentmeta-analysis of cancer cachexia conclude that current
data support a modular concept of cancer cachexia with
a variable combination of reduced nutritional intake and
catabolic/hypermetabolic changes.
Cachexia occurs in the majority of terminal cancer
patients and is responsible for the deaths of 22% of cancer
patients [5]. Importantly, survival of cancer patient suffering
from different types of neoplasias is dependent on the
amount of weight loss [6]. Therefore, cachexia represents
an important factor in the treatment of a cancer patient,
affecting not only survival, but also the efficacy of anticancer
treatment, quality of life, and medical costs. Thus there is
a strong pressure to better understand the mechanisms that
drive cachexia in order to offer cancer patients more effective
care.
Here we will discuss the impact of nonmuscle tissues,
only the ones that have a certain role; that is, kidney and
lung do not seem to have a role in cancer cachexia. Indeed
recent developments suggest that tissues/organs such as
adipose (both brown and white), brain, liver, gut, and heart
are directly involved in the cachectic process and may be
responsible for muscle wasting. This suggests that cachexia
is indeed a multiorgan syndrome (Figure 1).
2. Brain
Although a recent study involving 1853 cancer patients [7]
did not find common genetic causes in appetite loss in
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Figure 1: Interactions between different tissues/organs and skeletal muscle in the development of wasting associated with cancer cachexia.
The events and metabolic alterations that take place in different tissues/organs during cancer cachexia may be related with the loss of muscle
tissue. Indeed, muscle wasting may be influenced by the liver, inflammatory response, and by adipose tissues, particularly white fat. Brown
adipose tissue could partially account for the energy inefficiency associated with hypermetabolism in the cancer patient. Brain, basically
by modulation of appetite, also contributes to muscle wasting. The gut may be responsible for both malabsorption and changes in ghrelin
production and, finally, the heart could also be a source of inflammatory mediators contributing to further muscle wasting.
cancer patients, cytokines, neuroendocrine changes, and
tumour mediators are the main signals involved in appetite
depression in cachexia. Additional factors contributing to
the anorectic state are altered taste perception, therapy-
induced side effects [8], depressed motor activity, possible
mechanical interference on the gastrointestinal tract, and,
of course, psychological factors [9]. Indeed, patients with
cachexia often experience psychological distress as a result of
the uncertainties of the disease, its diagnosis, its treatment,
and its anticipated and final outcome [9]. This psychological
state, which often involves depression, is bound to affect
food intake. Both the limbic system and the brain stem
participate in the regulation of appetite and energy balance.
Thus, morphologically defined regions of the hypothalamus,
the arcuate nucleus (ARC), the paraventricular nucleus
(PVN), the dorsomedial nucleus (DMH), the ventromedial
nucleus (VMH), the lateral hypothalamic area (LHA), and
the perifornical area (PFA), appear to play a major role in
the regulation of body weight. There are two primary neuron
types within the ARC that integrate signals of nutritional
status and influence energy homeostasis: a subpopulation
of neurons in the medial ARC expresses the orexigenic
neuropeptides (neuropeptide Y (NPY) and agouti-related
peptide (AgRP)). More laterally there is a second subpopu-
lation that inhibits food intake via the expression of cocaine-
and amphetamine-regulated transcript (CART) and proop-
iomelanocortin (POMC), which is processed to melanocyte
stimulating hormone (MSH). Specific neuropeptides are
involved in the signalling of the neuronal circuits within these
regions of the hypothalamus, for instance, corticotrophin-
releasing hormone (CRH), thyrotropin-releasing hormone
(TRH), NPY, brain-derived neurotrophic factor (BDNF),
orexin, and melanin-concentrating hormone (MCH). The
brain stem also plays an important role in the regulation
of energy balance. Reciprocal connections are present, in
an extensive way, between the hypothalamus and brain
stem, particularly at the level of the nucleus tractus solitarii
(NTS). This nucleus is in close anatomical proximity to
the area postrema, a circumventricular organ that has an
incomplete blood brain barrier. Like the ARC, the NTS is
therefore located in an ideal place to respond to peripheral
circulating signals but in addition also receives vagal afferent
signals from the gastrointestinal tract and afferents from the
glossopharyngeal nerves.
Therefore, brain mediators involved in the control of
food intake, appetite, satiation, taste, and smell of food, are
responsible for the anorexia of the cancer patient, making the
brain a main organ responsible for one of the components of
the altered energy balance in cancer patients [10] (Figure 1).
Although anorexia represents a very important factor in the
development of cachexia, it has to be pointed out that in
many cases the use of total parenteral nutrition does not
stop the loss of body weight [11]. In addition to anorexia, the
hypothalamus via themelanocortin systemmay contribute to
muscle wasting via neuronal output, as suggested by different
animal studies [12, 13].
3. Gut
Gut-barrier dysfunction is a syndrome characterized by both
breakdown and leakage of the gut epithelial barrier, leading
to systemic inflammation due to the entry of bacterial cell
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wall components (endotoxin or lipopolysaccharide), or intact
bacteria into the circulation. Gut-barrier dysfunction is often
observed during the course of cancer cachexia [14] (Figure 1)
and is partially connected to radiochemotherapy treatment.
Additionally, tumour growth or macrophage infiltration at
the level of the intestinal wall may affect gastrointestinal
permeability, either locally or throughout the intestine via
alterations in epithelial tight junctions [15]. From this point
of view, tight junction proteins, such as ZO-1 and occludin,
show decreased expression in tumour-rich regions of the
intestine and colon in humans [16]. Decreases in tight
junction proteins would increase permeability and allow
passage of large molecules such as lipopolysaccharide (LPS)
into the lymphatic circulation. Changes in mucin secretion
and profiles in gastrointestinal carcinomas may become a
source of inflammation in the course of cancer cachexia [17].
Indeed, gut-barrier dysfunction may lead to endotoxemia
and, therefore, increased inflammation in cancer patients
[14].
In addition to the gut-barrier dysfunction syndrome,
recent studies support a role for gut microbiota in can-
cer cachexia. Indeed, decreased levels of bacteria, which
have immunomodulating properties, are decreased during
experimental cancer cachexia [18]. The existence of a gut-
microbiota-skeletal muscle axis has been reported [19]; in
fact, gut microbiota generates metabolites that can reach
skeletal muscle and influence energy expenditure in the
muscle cells [20].
Other aspects related with the gut may be beneficial for
cachectic patients. Ghrelin is the first identified circulating
hunger hormone that influences body weight regulation via a
vagal pathway [21]; it is a gastric hormone initially identified
in the rat stomach, in 1999, as an endogenous ligand for
the growth hormone secretagogue receptor (GHSR) [21].
Under fasting conditions, the stomach, through endocrine
cells located in the antrum, secretes ghrelin into the blood-
stream. The hormone acts as a “hunger” mediator that
signals the gastrointestinal fuel status from the periphery
to the central nervous system in order to stimulate food
intake and to adjust energy balance through decreasing
energy expenditure [22]. Ghrelin also binds to the GHSR1a
splice-variant that is enriched in the hypothalamus, as well
as other brain regions. In the hypothalamus, at the level
of the ARC, ghrelin contributes to enhanced food intake
by activating orexigenic mediators such as NPY, gamma-
aminoisobutyrate (GABA), andAgRP, and inhibiting anorex-
igenic mediators such as POMC, MSH, and CART [23]. The
GHSR1a receptor is also present on vagal afferents [24] and,
therefore, there is also strong evidence that ghrelin has a
peripheral effect on satiety by affecting the mechanosensi-
tivity of upper gastrointestinal vagal afferents, making them
less sensitive to distension which can result in overeating.
Ghrelin also has potent effects on fat storage. Ghrelin
activates white adipocytes [25] while doing the opposite
to brown adipocytes, therefore contributing to decreased
energy expenditure [26]. These effects are related with the
capacity of the hormone to stimulate growth hormone
(GH) release from the anterior pituitary [27]. In addi-
tion, ghrelin increases insulin-like growth factor 1 (IGF-1)
by stimulating its own receptor. These two factors are major
signals being related with the regulation of energy home-
ostasis. The effects of ghrelin on GH and IGF-1 may be
linked to the capacity of the hormone to prevent increases
in protein degradation, through different components of the
proteasome such asMuRF1 andMAFbx, at the level of skeletal
muscle. This is particularly relevant to cancer cachexia since
muscle wasting occurs mainly through activation of the
ubiquitin-dependent proteolytic system. Ghrelin levels are
elevated in cancer cachectic patients with neuroendocrine
[28], gastric [29, 30] and lung [31] tumours. These elevated
levels could represent a counterregulatory mechanism to
fight anorexia associated with tumour growth. It is, in fact,
an endocrine response to the so-called “ghrelin resistance”
found in cancer patients. Indeed, this is, in part, the reason
for the high doses of ghrelin used in clinical studies to
counteract anorexia in cancer. In clinical practice the use
of ghrelin and ghrelin agonists has led to promising results
in cancer cachectic patients. Ghrelin treatment improves
physical performance and muscle force indicating that the
peptide is the best candidate for muscle wasting treatment
either alone or in combinationwith other drugs or nutritional
strategies [32–37]. Therefore, future research is needed to
search for the optimal combination. Cancer cachexia is a
multiorgan syndrome affecting not only skeletal muscle but
also adipose tissues, heart, intestine, kidney, and liver. In
fact, the final cause of death in cachectic cancer patients
is, apart from the primary tumour itself, either sudden
death (heart arrhythmias, hypoventilation), thromboembolic
events (platelet aggregation), cardiorenal alterations (kidney
dysfunction), or compromised immune function (immuno-
suppression). Ghrelin has a beneficial effect in all of the
referred tissues.The only concern in treating cachectic cancer
patients relates to the fact that ghrelin may contribute to
tumour cell proliferation [38]. Indeed, ghrelin may increase
the levels of growth factors, such as GH and IGF-1 that
stimulate tumour growth. Additionally, ghrelin itself may
have mitogenic potential. As far as we know, no in vivo data
has examined the differences in tumour growth following
ghrelin or GHS treatment. Long-term, large-scale clinical
trials are required to determine whether ghrelin treatment
promotes tumour growth.
In addition to the role of the gut ghrelin in the control of
food intake, other mediators are bound to be involved in the
anorexia associated with the cachexia syndrome. From this
point of view,melanocortin-4 receptor [39] or prostaglandins
[40, 41] may work independently or alongside ghrelin.
4. Liver
The liver plays a key role in regulating whole-body meta-
bolism. Claude Bernard introduced the idea that the liver
is the “glucostat” of the organism, by regulating glucose
production and levels in mammals. Indeed, the liver can be
regarded as the central node of supply and utilization of fuel
by the tissues, the direction and flux of which are mediated
by the endocrine system [42].
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During catabolic conditions, opposing patterns of pro-
tein metabolism are observed between skeletal muscle and
liver. While skeletal muscle is under negative nitrogen
balance, mainly due to enhanced protein degradation, the
liver exhibits important changes in the patterns of pro-
tein synthesis such as increased production of acute-phase
proteins [42]. The enhanced muscle proteolysis drives a
large release of amino acids from skeletal muscle, such as
alanine and glutamine [43]. While glutamine is taken up
by tumour cells to sustain both the energy and nitrogen
demands of the growing mass, alanine is mainly channeled
to the liver for both gluconeogenesis and protein synthesis
[43]. Indeed, liver fractions from tumour-bearing animals
show increased production of acute-phase proteins including
C-reactive protein (CRP), serum amyloid A (SAA), 𝛼1-
antitrypsin, fibrinogen, and complement factors B and C3
and a decrease in the synthesis of transferrin and albumin,
leading to hypoalbuminemia [44]. An acute-phase response
is also observed in cancer patients. In addition, in cancer
patients with advanced cancer and during the fasting state,
the total albumin synthesis rate is unchanged, compared with
controls, despite much lower albumin concentrations [45].
Although the function of these proteins is far from being
clear, it is known that CRP contributes to the activation of
complement factors, enhancement of phagocytosis, and regu-
lation of cell immunity; 𝛼1-acid glycoprotein inhibits platelet
aggregation and phagocytosis andmay be involved in spacing
collagen fibres; haptoglobin binds to and clears haemoglobin
from plasma; 𝛼1-antitrypsin and 𝛼2-macroglobulin regulate
serine-proteases; and ceruloplasmin is probably involved in
copper transport. Recently, a link between SAA, in synergy
with interleukin-6 (IL-6), and activation of muscle proteoly-
sis has been described [46] (Figure 2).
During cancer, the patient’s inflammatory response
(Figure 1) is linked to weight loss and poor performance
status. Indeed, many inflammatory mediators are able to
influence different metabolic pathways related to cachexia [2,
43].The liver is an important contributor to the inflammation
observed in cancer. Indeed, CRP seems to be a very important
prognostic parameter [47–49].
The liver can also contribute to energy inefficiency.
Indeed, Dumas et al. found that the efficiency of oxidative
phosphorylation in liver mitochondria was decreased in
a rat model of peritoneal carcinosis, suggesting that this
may also contribute to hypermetabolism, elevated energy
expenditure, in cancer-bearing states [50]. These alterations
were associated with the content and fatty acid composition
of cardiolipins [51]. Indeed, the phospholipid composition
and especially cardiolipins are crucial for the mitochondrial
energy metabolism. Indeed, cardiolipin is known to provide
essential structural and functional support to several proteins
involved in oxidative phosphorylation.
Moreover, it has been described that a higher number
of CD68 immunoreactive macrophages have been found in
liver cross sections of patients with pancreatic cancer and
cachexia, suggesting that a crucial interaction between the
tumor, peripheral blood mononuclear cells (PBMCs), and
the liver, may play a central role in the development and




















Figure 2: Examples of cross talk between adipose tissue/liver and
skeletalmuscle during cancer cachexia. Adipose tissue releases some
factor(s), possibly fatty acids, that seem to be essential to acti-
vate muscle proteolysis. Indeed, recent evidences, using knockout
deficient mice, suggest that blocking lipolysis in white fat results
in an amelioration of muscle wasting. Similarly, liver acute-phase
proteins (APP), such as serum amyloid A (SAA), could participate,
alone or in synergy with cytokines, in activating muscle wasting by
enhancing protein degradation.
5. Heart
Cancer is associated with severe heart alterations. Indeed,
tumours implanted in experimental animals result in a
decrease of the heart weight [53, 54], accompanied by func-
tional cardiac changes, similar to those found in congestive
heart failure. According to Schünemann et al. “cancer fatigue
syndrome reflects clinically non-overt heart failure,” clearly
attributing a main role for heart abnormalities in the fatigue
of cancer patient [55]. Tian et al. suggested that cardiac
alterations in amouse cancer cachexiamodel includemarked
fibrosis, disrupted myocardial ultrastructure, and altered
composition of contractile proteins, such as troponin I and
MyosinHeavyChain-𝛼 (MHC-𝛼) [56]. Similarly,Mühlfeld et
al. using the well-established cachectic tumour rodent model
Lewis lung carcinoma observed changes in heart innervation
with the total number of axons in the left ventricle being
reduced as a consequence of tumour burden [57].This altered
innervation was associated with a reduced expression of
nerve growth factor [57]. The impairment of heart function
observed in tumour-bearing animals seems to be specifically
related to cardiac remodelling. Indeed, Tian et al. using
the mouse C26 tumour model showed increased cardiac B-
type natriuretic peptide (BNP) and c-fos expression together
with decreased Peroxisome Proliferator Activator Receptor-
𝛼 (PPAR-𝛼) and its responsive gene Carnitine Palmitoyl
Acyl Transferase-1𝛽 (CPT-1𝛽) and a switch from “adult”
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isoforms (MHC-𝛼, GLUT4) to “foetal” isoforms (MHC-
𝛽, GLUT1) [58]. The heart atrophy seems to be to some
extent related with increased cardiac muscle proteolysis,
since protein ubiquitination and expression of MuRF-1 and
atrogin-1 are elevated [58]. However, Cosper and Leinwand
suggest that the cardiac proteolysis is rather caused by
increased autophagy [59], in a converse manner to what
happens in skeletal muscle. Interestingly, inhibition of NF-𝜅B
protects against tumour-induced cardiac atrophy, at least in
experimental animals [60]. Cardiac atrophy in experimental
cancer cachexia has recently been related with a high affinity
activin type 2 receptor (ActRII) that mediates the signalling
by a subset of Transforming Growth Factor-Beta (TGF-
𝛽) family ligands including myostatin, activin, and GDF11.
Blocking pharmacologically this receptor reverses cancer-
induced atrophy of the heart [61].
In addition to cardiac atrophy, Drott and Lundholm
observed an increase in oxygen consumption, most likely
related with the anaemia that very often is present in cancer
patients, in the heart of an experimental cancer rodent model
[62]. Important ultrastructural changes were also observed,
such as an increase in the ratio of myofibrils/mitochondria
and sarcomeric alterations, similar to those observed during
cardiac failure. The increased oxygen consumption can to
some extent be associated with increased energy expenditure,
thus making the heart an additional organ involved in
generating energy inefficiently (Figure 1). Indeed, heart rate
seems to be elevated in cancer patients [63]. In fact, this
parameter seems to be a very effective measure of cancer
death risk.Themechanisms that could explain the association
between heart rate and cancer mortality are unclear. Heart
rate increase might be a marker of chronic stress and anxiety,
which represent a natural consequence of the disease.
6. Adipose Tissues
6.1. White Adipose Tissue (WAT) and Muscle Wasting. Previ-
ous studies have emphasized the cross talk between adipose
tissue and skeletal muscle. Indeed, signals released from both
tissues, that is, Tumour Necrosis Factor-𝛼 (TNF-𝛼), IL-6, and
interleukin-15 (IL-15), may participate in a reciprocal manner
in the regulation of adipose and muscle tissue mass [64, 65].
Irisin, a protein produced both in skeletal muscle and adipose
tissue in response to exercise, is able to stimulate browning of
adipose tissue [66].The release of irisin seems to be promoted
by the transcriptional coactivator PPAR-𝛼 coactivator-1 alpha
(PGC-1𝛼) [67]. Very interestingly, the blockade of myostatin
drives browning of adipose tissue through activation of the
PGC-1𝛼-irisin pathway [68]. Alterations in the balance of
the signals could well be associated possibly with obesity,
diabetes, or cachexia [64, 65]. Indeed, the adipocyte releases
TNF-𝛼 and other cytokines that have a direct effect on
muscle metabolism. Similarly, skeletal muscle releases IL-6,
IL-15, and other signals that interfere with fat metabolism
[64, 65]. Loss of fat mass is a key feature of cancer cachexia
and the mechanism that drives this is multifactorial. On
the one hand, lipolysis is activated in the adipocyte, which
reduces its cellular volume [69]. Lipolysis may be favoured
by a dramatic decrease in perilipin [70], a protein that acts
as a protective coating from different lipases. The intense
lipolysis is accompanied by changes in the expression of genes
that regulate energy turnover, cytoskeleton, and extracellular
matrix, suggesting high tissue remodelling. Altogether, this
results in not only a net loss of the triglyceride depot, but
also a change in the phenotype of the fat cell. On the other
hand, fat depletion associated with cancer is linked with a
decrease uptake of VLDL and chylomicron triacylglycerol
due to a decrease in lipoprotein lipase (LPL) activity [2]. The
increased fat removal is accompanied by a decrease in the
rate of de novo lipogenesis in the adipocyte [2]. Interestingly,
during cachexia a concomitant inhibition of adipogenesis
takes place, possibly triggered by PPAR-𝛼 [71].
Both hormonal changes, insulin resistance and hyper-
glucagonemia, and release of proinflammatory cytokines
seem to be responsible for the changes in adipocyte
metabolism. In addition, both in experimental animals and
humans, a zinc-𝛼2 glycoprotein (ZAG) has been associated
with the increased lipolytic rate [72]. ZAG, released by
the tumour, seems to be the mediator able to activate the
triacylglycerol lipase responsible for the increased lipolysis
associated with cancer cachexia.
Das et al. found that genetic ablation of adipose triglyc-
eride lipase (ATGL) in the mouse resulted in a prevention
of increased lipolysis and, therefore, reduction in WAT,
associated with tumour burden [73]. Interestingly, ablation
of hormone-sensitive lipase (HSL) leads to similar but
less marked effects [73]. Interestingly, the lipolytic ablation
resulted in a preservation of skeletal muscle mass, suggesting
that the breakdown of fat precedes that of skeletal muscle
proteins and implicating that some signal(s) generated during
the breakdown of adipocyte triacylglycerols may actually
activate muscle proteolysis (Figure 2). The ablation of the
mentioned lipase was also associated with a lack of activation
of the main proteolytic system involved in muscle wasting
during cancer, which is that of the ubiquitin-proteasome
pathway [73]. In addition to the changes related to adipose
tissue itself, infiltration of adipose tissue in skeletal muscle
could contribute to wasting in this tissue. From this point of
view Stephens et al. [74] have reported increased presence of
intramyocellular lipid droplets in rectus abdominismuscle of
cancer patients, which seems to be related to body weight loss
in these patients.
6.2. Brown Adipose Tissue (BAT) and Energetic Inefficiency.
The metabolic energetic inefficiency, linked to hyperme-
tabolism, found in the cancer patient, seems to be responsible,
together with the reduced food intake, for the negative energy
balance found in the patient [1]. Hypermetabolism seems
to be related with inflammation [43]. Many futile cycles
are responsible for hypermetabolism, including increased
Cori Cycle activity between the liver and the tumour [75],
liver glycolysis/gluconeogenesis [76], muscle protein syn-
thesis/degradation [77], and adipose tissue triacylglycerol
recycling [78]. An alternative mechanism contributing to
hypermetabolism is the mitochondrial uncoupling proteins,
originally described in BAT. Until quite recently, BAT has
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been considered as a thermogenic organ in rodents. By burn-
ing fat, BAT provides fatty acids which are further oxidized
but, instead of serving for mitochondrial ATP synthesis,
the energy associated with the oxidative process is released
as heat due to the existence in the inner mitochondrial
membrane of uncoupling proteins that permeabilize? the
mitochondrial membrane to the electrochemical H+ gradient
that drivesATP synthesis [79]. In 2009,Virtanen et al. showed
that BAT was present in adult humans in the upper back,
in the neck, between the collarbone and shoulder, and also
along the spine, suggesting also a function for BAT in humans
[80]. Recent data suggest the existence of two different types
of brown adipose tissue cells: in addition to the “classical”
uncoupling protein 1, UCP1 positive, derived from a myf-
5 cellular lineage, so-called “beige” adipose cell exists with
very low UCP1 expression and is derived from a non-myf-
5 cellular lineage. Beige cells have their own gene pattern
expression, different from both white and brown cells, and
respond preferably to irisin [81]. Until now, no information
is available concerning a possible role of these cells in cancer
cachexia but certainly the topic deserves future attention.
Since BAT plays a key role in thermogenesis and energy
balance, it may potentially contribute to the physiologic
perturbations associated with cachexia (Figure 1). Several
reports in experimental animals already point out a clear
activation of BATduring cancer cachexia. Recently, Tsoli et al.
have demonstrated increased BAT thermogenesis in cachec-
tic tumour-bearing mice due to increased UCP1 or lipid oxi-
dation (CPT-1𝛼 and peroxisomal bifunctional enzyme (PBE),
one of the four enzymes of the peroxisomal beta-oxidation
pathway) [82]. The changes observed seem to be related to
an activation of STAT-3, possibly via IL-6. Unfortunately, no
information is available on the role of brown fat in human
cancer cachexia; therefore future research on this aspect is
strongly encouraged.
In addition, there is another aspect to bear into consider-
ation related to patients with cancer. Since the observation
of the existence of BAT in adult humans, a population of
cells, within WAT, which has the same characteristics as
brown adipocytes, have been described [83, 84]. These cells
are known as BRITE (brown into white) and seem to appear
in WAT under certain conditions that seem to involve the
COX-2 prostaglandin pathway. Both BAT and BRITE cells
are more sensitive to insulin than WAT ones; therefore they
consume glucose at a higher rate. Since both insulin and IGF-1
have been reported to fuel some tumours, havingmore or less
BAT may affect the overall systemic insulin sensitivity and
thereby have an indirect influence of tumour progression.
7. Conclusions and Future Directions
Since human skeletal muscle represents almost 50% of
body weight, research on cancer wasting has for a long
time been mainly devoted to this skeletal tissue. However,
cancer cachexia is indeed a multiorgan syndrome affecting
many types of cells, including adipose tissues, heart, liver,
gastrointestinal tract, and brain. It has been recently reported
that mediators released in nonmuscle tissues, during the
cachexia syndrome, may actually be directly responsible for
the activation of the metabolic alterations, such as increased
protein degradation [85, 86], apoptosis [87, 88], and altered
regeneration [89], leading to skeletal muscle wasting.
The implications of this are important since, on the one
hand, the metabolic alterations affecting all cellular types
may be very relevant to the understanding of the cachexia
syndrome and, secondly, the development of new therapeutic
approaches may benefit from this knowledge: for instance,
it may be relevant to interfering with lipolysis or with
acute-phase protein synthesis to block muscle proteolysis.
Therefore, future studies on this field are needed and should
concentrate on unrevealing the different mediators released
by nonmuscle tissues that may influence muscle metabolism
and, therefore, wasting. Furthermore, another important
aspect that future research should contemplate is to establish
the chronological involvement of the different organs/tissues
in cancer cachexia.
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